Celcuity Inc Stock Price, News & Analysis

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has announced it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss results and provide a corporate update. Domestic callers can dial 1-800-717-1738, while international callers should use 1-646-307-1865 to participate.

Celcuity Inc. (Nasdaq: CELC) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Plan to initiate Phase 3 VIKTORIA-2 trial for gedatolisib in HR+, HER2- advanced breast cancer, with first patient enrollment expected in Q2 2025.

2. VIKTORIA-1 PIK3CA WT cohort enrollment target expected in Q4 2024, with topline data anticipated in late Q4 2024 or Q1 2025.

3. Raised $129 million in gross proceeds from equity and debt financings, extending operational runway through 2026.

4. Q2 2024 financial results: Total operating expenses of $24.3 million, net loss of $23.7 million ($0.62 per share), and cash position of $283.1 million as of June 30, 2024.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced the schedule for its second quarter 2024 financial results release. The company will disclose its financial performance after the market closes on Wednesday, August 14, 2024. Following the release, management will host a webcast and teleconference at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Investors and interested parties can participate in the teleconference by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Additionally, a live webcast presentation will be accessible via the provided weblink. For those unable to attend the live event, a replay of the webcast will be made available on the Celcuity website.

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology firm focused on oncology therapies, announced its participation in the Jefferies Global Healthcare Conference from June 4-6, 2024, in New York.

Brian Sullivan, CEO and Co-founder, will engage in a fireside chat at 10:00 a.m. ET on June 6, 2024.

The event will be webcast live at this link: https://wsw.com/webcast/jeff302/celc/1809904, and accessible via the Investors section on Celcuity's website, with a replay available soon after.

Celcuity (NASDAQ: CELC), a clinical-stage biotechnology company, announced the pricing of an underwritten offering of 3,871,000 shares of common stock at $15.50 per share, aiming to raise $60 million. Notable investors include BVF Partners L.P., Vivo Capital, and Eventide Asset Management. The offering is expected to close by May 31, 2024, pending customary conditions.

Proceeds are earmarked for working capital, corporate purposes, and a Phase 3 trial for advanced breast cancer treatment. Combined with existing cash and investments, these funds should cover expenses through late 2026. Leerink Partners, TD Cowen, and Stifel are joint bookrunning managers. The offering is registered under a previous SEC filing.

Celcuity announced plans to initiate a Phase 3 trial for gedatolisib as first-line treatment for HR+/HER2- advanced breast cancer. The trial will assess gedatolisib combined with a CDK4/6 inhibitor and fulvestrant, targeting patients resistant to endocrine therapy. Initial trial results show promising efficacy, with a median progression-free survival of 48.6 months and an overall response rate of 79% in Phase 1b. Additionally, Celcuity secured $62 million in debt financing to support this initiative, amending its agreement with Innovatus Capital Partners and adding Oxford Finance as a new lender, increasing the total debt facility to $180 million. The Phase 3 trial, named VIKTORIA-2, will involve approximately 638 subjects across 200 global sites, with enrollment beginning in Q2 2025.

Celcuity Inc. (Nasdaq: CELC) reported its first-quarter financial results and provided a corporate update. The Phase 3 VIKTORIA-1 trial remains on track, with topline data expected in the second half of 2024. The company also initiated a Phase 1b/2 trial for gedatolisib in prostate cancer, and dosed its first patient in February 2024. Financial highlights include a net loss of $21.6 million ($0.64 per share) for Q1 2024, compared to $11.9 million ($0.55 per share) in Q1 2023. Operating expenses rose to $22.5 million from $12.6 million year-over-year. Cash reserves stand at $177.7 million, expected to fund operations into early 2026.

Celcuity Inc. (Nasdaq: CELC) will release its first quarter 2024 financial results on May 15, 2024, with a webcast/conference call hosted by management to discuss the results and provide a corporate update. The company is a clinical-stage biotechnology firm developing targeted oncology therapies.